Abstract
Over the last 20 years, umbilical cord blood(UCB) has become an increasingly used source of hematopoeitic stem cells for transplantation. For pediatric patients, UCB is now routinely utilized as a source of stem cells. However, the median age of presentation of most hematologic malignancies is in the 5th and 6th decades of life, a time when other co-morbidities are more likely. Also, patients are frequently referred to transplantation after extensive prior therapy, including prior autologous transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
